Current Responsibilities: Charbel Haber joined Moderna in April 2020 as a Senior Vice-President of Regulatory Affairs.  In this role, Charbel is responsible of building a global regulatory organization, comprising, Regulatory Operations, Regulatory CMC, and Regulatory Strategy, to support Moderna’s pipeline including the development and registration of Moderna COVID-19 Vaccine. 

Prior Experience: Charbel worked most recently at Biogen, where he was a VP in Global Safety and Regulatory Sciences leading the Global Regulatory Strategy, Medical Writing, and the Clinical Trial Application team.   Charbel has an extensive and diverse global regulatory background having worked at EMD Serono, Novartis (both in the US and in EU), PTC Therapeutics, MedImmune and Merck. His experiences include both large and small molecules across a number of modalities and therapeutic areas spanning gene therapy, vaccines, biologics, Anti-Sense Oligonucleotides, orphan, neurological, respiratory, cardiovascular, inflammatory, and auto-immune diseases. Of particular note, Charbel led the regulatory development and registration of the Fluvirin-H1N1 vaccine at Novartis during the H1N1 Flu pandemic in 2009.

Education:  Charbel holds a PhD in Chemical and Biomolecular Engineering from the Johns Hopkins University, a Masters’ degree in Public Health from Thomas Jefferson University, and an MBA from Thunderbird School of Global Management.